This project is to use genetic engineered “cold-sore” virus to treat prostate cancer. The virus is engineered to reduce its toxicity to normal tissues but can specifically attack and kill tumour cells. Meanwhile, the virus releases a group of anti-tumour immune stimulating factors to activate immune system to eliminate prostate tumour. This project will use […]

In Canada, lung cancer is the leading cause of cancer-related deaths for both sexes. Non-small-cell lung cancer (NSCLC) constitutes ~85% of lung cancer cases. Mutations in the KRAS and EGFR genes are two most common oncogenic drivers for NSCLC and responsible for ~30% and ~15% of NSCLCs, respectively. Unlike the EGFR-mutant type, KRAS-mutant NSCLC is […]

Modern molecularly targeted therapies have shown promise in treating some blood cancers, but a cure remains elusive for most acute blood cancer patients. This is largely due to the survival of some blood cancer cells that possess unique properties and can cause treatment failure or relapse, highlighting the need for new therapies. In collaboration with […]